Rocket Pharmaceuticals (NasdaqGM:RCKT) FY Conference Transcript

Summary of Rocket Pharmaceuticals FY Conference Call Company Overview - Company: Rocket Pharmaceuticals (NasdaqGM:RCKT) - Industry: Gene Therapy, focusing on rare cardiac diseases and hematology/immunology - Financial Position: As of the end of last year, the company had $189 million, sufficient to cover cash needs into Q2 2027 [2][3] Key Milestones and Programs 1. Kresladi (LAD-I ex vivo Lenti program) - Potential FDA approval with a PDUFA date of March 28, 2026 - Targets primary immunodeficiency in children, with a focus on commercialization and non-dilutive financing opportunities [3][4] - The program has shown a Kaplan-Meier curve with 100% survival over 5+ years in some cases [13] 2. Danon Disease - Affects boys more than girls, with a high mortality rate before age 20 - Phase 1 data published showing prolonged protein expression and heart function improvement in treated patients [5][6] - Currently in a pivotal phase 2 trial, with adjustments made to the immunomodulation regimen to enhance safety [6][7] - The trial design includes a 12-patient single-arm trial with primary endpoints focused on LV mass index and protein expression [7] 3. PKP2 (Arrhythmogenic Cardiomyopathy) - Treated three patients in a phase 1 trial, showing moderate improvements in arrhythmias and right ventricular function [8][9] - Discussions with the FDA are ongoing to finalize the pivotal phase 2 trial design [9] 4. BAG3 (Dilated Cardiomyopathy) - Anticipated to start a phase 1 trial this year, with an open IND [9][10] - Represents a significant opportunity in the DCM space, with potential to capture a large patient population [10][48] Market and Regulatory Insights - The company is focusing on rare cardiac diseases, which are often fatal or highly debilitating, aligning with FDA's pro-rare disease stance [28][29] - The addressable market for these diseases remains significant, with ongoing epidemiological research to refine patient estimates [35][36] - The company aims to partner its LV portfolio to maximize patient access and shareholder value [12][14] Safety and Efficacy Considerations - Emphasis on safety improvements in gene therapy, particularly in the Danon program, where previous safety issues were addressed [21][22] - The company is cautious about trial designs and patient treatment protocols, ensuring thorough analysis and collaboration with regulatory bodies [20][24] Underappreciated Aspects - The evolution of the company in gene therapy, focusing on transparency, deliberate risk-taking, and resource allocation, positions Rocket Pharmaceuticals as a potential leader in the field [56] Conclusion Rocket Pharmaceuticals is strategically advancing its gene therapy programs for rare cardiac diseases, with significant milestones on the horizon. The company is committed to safety and efficacy while navigating regulatory landscapes and market opportunities.